FOMX News and Press, Foamix Pharmaceuticals Ltd. From 09/15/19

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 120 weeks of public selections as part of this ongoing live forward-testing. In...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 121 weeks of public selections as part of this ongoing live forward-testing. In...

REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical thera...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 119 weeks of public selections as part of this ongoing live forward-testing. In...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. ...

Gainers:  Mmtec (NASDAQ: MTC ) +346% . Deciphera Pharmaceuticals (NASDAQ: DCPH ) +87% . PEDEVCO (NYSEMKT: PED ) +40% . Mustang Bio (NASDAQ: MBIO ) +24% . OptiNose (NASDAQ: OPTN ) +22% . LSC Communications (NYSE: LKSD ) +21% . Foamix Pharmaceuticals (NASDAQ: FOMX ) +18% . Jumia ...

Foamix Pharmaceuticals ( FOMX ) is a biotech that should be on everyone's radar, especially as it approaches to potentially have 2 FDA approvals under its belt. This involves the NDA that was filed just this past week for FMX103 to treat moderate to severe papulopustular rosacea. On top of t...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 117 weeks of public selections as part of this ongoing live forward-testing. In...

Foamix Pharmaceuticals Ltd. (FOMX) Q2 2019 Earnings Conference Call August 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial...

Foamix Pharmaceuticals (NASDAQ: FOMX ): Q2 GAAP EPS of -$0.35 beats by $0.02 . More news on: Foamix Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...